Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 4.34 1.40% 0.06
CTXR closed up 1.4 percent on Friday, January 19, 2018, on 63 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Up
See historical CTXR trend table...

Date Alert Name Type % Chg
Jan 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 19 Doji - Bearish? Reversal 0.00%
Jan 19 Stochastic Reached Overbought Strength 0.00%
Jan 19 Weak + Overbought Other 0.00%
Jan 19 Wide Bands Range Expansion 0.00%
Jan 19 Weak, Overbought and Reversal Signs Reversal 0.00%
Jan 19 Overbought Stochastic Strength 0.00%
Jan 19 Up 3 Days in a Row Strength 0.00%
Jan 19 Upper Bollinger Band Touch Strength 0.00%
Jan 18 NR7 Range Contraction 1.40%

Older signals for CTXR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
Is CTXR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.49
52 Week Low 2.56
Average Volume 98,444
200-Day Moving Average 0.0
50-Day Moving Average 4.4577
20-Day Moving Average 4.077
10-Day Moving Average 4.047
Average True Range 0.3595
ADX 15.27
+DI 20.12
-DI 14.54
Chandelier Exit (Long, 3 ATRs ) 3.7415
Chandelier Exit (Short, 3 ATRs ) 4.5485
Upper Bollinger Band 4.3835
Lower Bollinger Band 3.7705
Percent B (%b) 0.93
BandWidth 15.035565
MACD Line -0.0656
MACD Signal Line -0.1063
MACD Histogram 0.0408
Fundamentals Value
Market Cap 35.81 Million
Num Shares 8.25 Million
EPS -1.98
Price-to-Earnings (P/E) Ratio -2.19
Price-to-Sales 0.00
Price-to-Book 1.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.70
Resistance 3 (R3) 4.70 4.57 4.64
Resistance 2 (R2) 4.57 4.48 4.58 4.62
Resistance 1 (R1) 4.46 4.43 4.52 4.46 4.60
Pivot Point 4.33 4.33 4.36 4.34 4.33
Support 1 (S1) 4.22 4.24 4.28 4.22 4.08
Support 2 (S2) 4.09 4.19 4.10 4.06
Support 3 (S3) 3.98 4.09 4.04
Support 4 (S4) 3.98